Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder

Pediatric Bipolar Disorder Clinical Trial

Official title:

A Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00592267
• Other study ID #: 2001-P-001247
• Status: Recruiting
• Start date: September 2001
• Est. completion date: December 2023

Study information

• Verified date: January 2022
• Source: Massachusetts General Hospital
• Contact: Rebecca Wolenski
• Phone: 617-643-6617
• Email: rwolenski[@]partners.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this protocol is to establish a comprehensive screening process for the evaluation of eligibility for entry in a clinical trial program for children and adolescents with bipolar disorder.

Description:

To address the urgent therapeutic needs of children and adolescents ages 4-17 with pediatric bipolar disorder, we have designed a series of clinical trials aimed at evaluating critical components of the treatment needs of this under-served and under-researched population. This approach will allow us to provide a full complement of clinical trials that will meet the most pressing needs of the bipolar children and adolescents and their families who are currently awaiting treatment.

Although these protocols have received prior IRB approval, potential participants present with a widely varied set of complaints not always discernable in a telephone screening interview. This state of affairs makes it very difficult to ask subjects to sign a specific clinical protocol without obtaining additional clinical information. Because of this we are proposing potential subjects to consent to undergo an in-depth clinical assessment that will allow subjects to be screened by a clinician for eligibility to a diverse clinical trials program available to them.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

• Males and females age 4 to 17 inclusive with a suspected diagnosis of bipolar disorder.

• Subject and parent/ legal guardian must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.

• Subjects and their parent/ legal representative must be considered reliable.

• Each subject and his/her parent or authorized legal representative must understand the nature of the study. The subject's parent or authorized legal representative must sign an informed consent document and the subject must sign an informed assent document.

• One parent/ legal guardian must be able to accompany the subject to the clinic at each visit.

Exclusion Criteria:

• Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.

• Serious, unstable illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease

• Mental retardation

Related Conditions & MeSH terms

• Bipolar Disorder
• Disease
• Pediatric Bipolar Disorder

Locations

Country	Name	City	State
United States	Masschusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Screening Protocol	This protocol is a prescreening for other research studies.	Study Enrollment

External Links

•   Related Info